دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Lower Impact of Disease on Daily Life and Less Fatigue in Patients With Inflammatory Bowel Disease Following a Lifestyle Intervention
Carlijn R Lamers, MD, Nicole M de Roos, PhD, Henrike H Heerink, MSc, Linda A van de Worp-Kalter, BSc, Ben J M Witteman, MD, PhD
doi : 10.1093/ibd/izac027
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1791–1799
Despite the potential benefits of diet and physical activity, evidence for beneficial effects of a combined lifestyle intervention is lacking in patients with inflammatory bowel disease (IBD). Therefore, we assessed its effects on impact of disease on daily life, clinical disease activity, fatigue, and health-related quality of life (HRQoL) in patients with IBD.
Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
Maria T Abreu, MD, Julie M Davies, PhD, Maria A Quintero, MD, Amber Delmas, MS, Sophia Diaz, MD, Catherine D Martinez, BS, Thomas Venables, BA, Adrian Reich, PhD, Gogce Crynen, PhD, Amar R Deshpande, MD, David H Kerman, MD, Oriana M Damas, MD, Irina Fernandez, MS, Ana M Santander, BS, Judith Pignac-Kobinger, MS, Juan F Burgueno, PhD, DVM, Mark S Sundrud, PhD
doi : 10.1093/ibd/izac151
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1800–1812
Inflammatory bowel disease (IBD) involves chronic T cell–mediated inflammatory responses. Vedolizumab (VDZ), a monoclonal antibody against α4β7 integrin, inhibits lymphocyte extravasation into intestinal mucosae and is effective in ulcerative colitis (UC) and Crohn’s disease (CD).
Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study
Pepijn W A Thomas, MD, Nathan den Broeder, MSc, Monique Derikx, MD, Wietske Kievit, PhD, Rachel L West, MD, PhD, Maurice G V M Russel, MD, PhD, Jeroen M Jansen, MD, Tessa E H Römkens, MD, PhD, Frank Hoentjen, MD, PhD
doi : 10.1093/ibd/izac002
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1813–1820
There are limited real-world data on the change in total work impairment (TWI) in biological-treated patients with inflammatory bowel disease (IBD). This study aimed to evaluate the real-world effects of initiating biological therapy or tofacitinib on change in TWI in IBD patients.
Early Pouchitis Is Associated With Crohn’s Disease–like Pouch Inflammation in Patients With Ulcerative Colitis
Maia Kayal, MD, MS, David Kohler, Michael Plietz, MD, Sergey Khaitov, MD, Patricia Sylla, MD, Alexander Greenstein, MD, MPH, Marla C Dubinsky, MD
doi : 10.1093/ibd/izac012
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1821–1825
Despite the initial diagnosis of ulcerative colitis (UC), approximately 10% to 20% of patients develop Crohn’s disease–like pouch inflammation (CDLPI) after restorative proctocolectomy (RPC) with ileal pouch anal anastomosis (IPAA). The aim of this study was to evaluate whether early pouchitis, defined as pouchitis within the first year after IPAA, is a predictor of CDLPI.
Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy
Simon J Hong, MD, Cameron Zenger, MD, Jillian Pecoriello, MD, Alice Pang, MD, Margaret Vallely, RN, David P Hudesman, MD, Shannon Chang, MD, MBA, Jordan E Axelrad, MD, MS
doi : 10.1093/ibd/izac035
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1826–1832
There is little data regarding the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a prior history of cancer who are exposed to ustekinumab or vedolizumab. We assessed the risk of subsequent cancer in patients exposed to these agents.
Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis
Saranya Sasidharan, MD, Alexa N Sasson, MD, Kevin M Shannon, BS, Ashwin N Ananthakrishnan, MD, MPH
doi : 10.1093/ibd/izac011
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1833–1837
Up to one-third of patients hospitalized for acute severe colitis secondary to inflammatory bowel diseases (IBD) do not adequately respond to intravenous steroids. There is an unmet need to identify a useful predictor for rescue treatment in this cohort of patients.
Food-Related Quality of Life in Children and Adolescents With Crohn’s Disease
Stephanie C Brown, MDiet, Kevin Whelan, PhD, Chris Frampton, Catherine L Wall, PhD, Richard B Gearry, MD, Andrew S Day, MD
doi : 10.1093/ibd/izac010
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1838–1843
Food-related quality of life (FRQoL) encompasses the psychosocial elements of eating and drinking. The FRQoL of children and adolescents with inflammatory bowel disease has not yet been assessed. This study aimed to evaluate the utility of the validated FR-Qol-29 instrument in children with Crohn’s disease (CD).
Sarcopenia Is More Prevalent Among Inflammatory Bowel Disease Patients Undergoing Surgery and Predicts Progression to Surgery Among Medically Treated Patients
James P Campbell, MD, Levi Teigen, PhD, RD, Scott Manski, MD, Brian Blumhof, MD, Flavius F Guglielmo, MD, Raina Shivashankar, MD, Eugenia Shmidt, MD
doi : 10.1093/ibd/izac013
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1844–1850
Sarcopenia is common in inflammatory bowel disease (IBD); however, estimates of its prevalence and impact on clinical outcomes are variable. This study sought to compare the prevalence of sarcopenia in IBD patients starting new biologics vs patients undergoing IBD surgeries, and its association with common clinical predictors of nutritional status, adverse events, and clinical outcomes.
A Mixed-methods Assessment of the Impact of Insurance Issues on the Emotional and Physical Health of Patients With Inflammatory Bowel Disease
Alicia Philippou, MD, Beselot Birhanu, BS, Anthony Biello, BA, Laurie Keefer, PhD, Ksenia Gorbenko, PhD
doi : 10.1093/ibd/izac022
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1851–1858
In patients with inflammatory bowel disease (IBD), failure to adhere to treatment regimens due to insurance issues can lead to disease complications. Our aim was to examine patients’ perceptions of the impact of insurance issues on their health.
Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn’s Disease
R Dawson, MBChB, D I F Wands, MBChB, M Logan, Phd, G Bremner, BSc, S Efklides, BSc, L Benn, BSc, P Henderson, Phd, H Grant, BSc, J Meredith, MBChB, K Armstrong, BScCN, D C Wilson, MD, K Gerasimidis, Phd, G Alex, Phd, R K Russell, Phd
doi : 10.1093/ibd/izac039
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1859–1864
Exclusive enteral nutrition (EEN) is the recommended induction treatment of mild to moderate active pediatric Crohn’s disease (CD). This study compared outcomes of 2 proprietary polymeric formulas. Treatment effectiveness was examined along with practical aspects of formula delivery and differences in estimated treatment costs.
Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn’s Disease
Yushan Pan, BA, Waseem Ahmed, MD, Prerna Mahtani, MS, Rochelle Wong, MD, Randy Longman, MD, PhD, Dana Jeremy Lukin, MD, PhD, Ellen J Scherl, MD, Robert Battat, MD, CM
doi : 10.1093/ibd/izac030
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1865–1871
In postoperative Crohn’s disease (POCD), data are lacking on relationships between serum biologic concentrations and treatment outcomes. We assessed if established threshold concentrations of infliximab (IFX), adalimumab (ADA), and ustekinumab (UST) impact outcomes in POCD.
Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial
Sharon Jedel, PsyD, Todd Beck, MA, Garth Swanson, MD, Megan M Hood, PhD, Robin M Voigt, PhD, Annika Gorenz, MA, Shriram Jakate, MD, Shohreh Raeisi, MA, Stevan Hobfoll, PhD, Ali Keshavarzian, MD
doi : 10.1093/ibd/izac036
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1872–1892
Ulcerative Colitis (UC) is a chronic, inflammatory disease, characterized by symptomatic periods (flare) interspersed with asymptomatic periods (remission).
Crohn’s Disease Patients Uniquely Contain Inflammatory Responses to Flagellin in a CD4 Effector Memory Subset
Nadine N Morgan, PhD, Lennard W Duck, BS, Jiongru Wu, PhD, Mahmud Rujani, BS, Paul G Thomes, PhD, Charles O Elson, MD, Peter J Mannon, MD
doi : 10.1093/ibd/izac146
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1893–1903
Specific microbial antigens stimulate production of antibodies indicative of the aberrant immune response in Crohn’s disease (CD). We tested for T cell reactivity linkage to B cell responses and now report on the prevalence, functionality, and phenotypic differences of flagellin-specific T cells among CD patients, ulcerative colitis (UC) patients, and control subjects and association with clinical features and flagellin seropositivity within CD patients.
The Relationship Between Opioid Use and Healthcare Utilization in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Jessica L Sheehan, MD, MS, Janson Jacob, MD, Elliot M Berinstein, MD, MSc, LaVana Greene-Higgs, MD, Calen A Steiner, MD, MS, Sameer K Berry, MD, Carol Shannon, MPH, MA, Shirley A Cohen-Mekelburg, MD, MSc, Peter D R Higgins, MD, PhD, MSc, Jeffrey A Berinstein, MD, MSc
doi : 10.1093/ibd/izac021
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1904–1914
Pain is commonly experienced by patients with inflammatory bowel disease (IBD). Unfortunately, pain management is a challenge in IBD care, as currently available analgesics are associated with adverse events. Our understanding of the impact of opioid use on healthcare utilization among IBD patients remains limited.
The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease
Seema A Patil, MD, Shubha Bhat, PharmD, MS, Jimmy K Limdi, MBBS, Francis A Farraye, MD, MSc, Raymond K Cross, MD, MS
doi : 10.1093/ibd/izac048
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1915–1923
Vitamin D Deficiency is Common in Patients with Ulcerative Colitis After Total Proctocolectomy with Ileal Pouch Anal Anastomosis
Anam Rizvi, MD, Parth Trivedi, MD, Ariel Bar-Mashiah, MD, Michael Plietz, MD, Sergey Khaitov, MD, Patricia Sylla, MD, Alexander Greenstein, MD, MPH, Marla C Dubinsky, MD, Maia Kayal, MD, MS
doi : 10.1093/ibd/izac093
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1924–1926
Risk Factors for Voluntary Childlessness in Men and Women With Inflammatory Bowel Disease
Rachel W Winter, MD, MPH, Taylor Boyd, BS, Walter W Chan, MD, MPH, Alexander N Levy, MD, Sonia Friedman, MD
doi : 10.1093/ibd/izac104
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1927–1931
Sarcopenia as a Risk Prediction Tool in Inflammatory Bowel Disease
Adam S Faye, MD, MS, John A Dodson, MD, MPH, Aasma Shaukat, MD, MPH
doi : 10.1093/ibd/izac069
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1932–1933,
Myocardial Infarction With Nonobstructive Coronary Arteries in New-onset Inflammatory Bowel Disease
Benjamin B Claxton, MD MPH, George Sun, BS, Ritu Nahar, MD, Christopher Henry, MD
doi : 10.1093/ibd/izac145
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1934–1935
A Rare Case of Protein-Losing Enteropathy, Alopecia, Hyperpigmentation and Dystrophy of the Nails: A Case Report
Jasper Vonk, MD, Rosalia J M Ader, MD, Marijn C Visschedijk, MD, PhD
doi : 10.1093/ibd/izac154
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages 1936–1937,
Correction to: Efficacy, Safety, and Tolerability of 
Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis
Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, Simon Lichtiger, Josep Bassaganya-Riera
doi : 10.1093/ibd/izac055
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Page 1938
Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy
Sudheer K Vuyyuru, MD, Mayur Brahmania, MD, Juan Pablo Arab, MD, Vipul Jairath, MB ChB, DPhil
doi : 10.1093/ibd/izac207
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Pages e150–e152
Reply to “Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy�
Ali Reza Safarpour, PhD, Sara Shojaei-Zarghani, PhD, Manoosh Mehrabi, PhD, Abbas Ali Keshtkar, PhD, Ali Akbar Oroojan, PhD, Gholam Reza Sivandzadeh, MD
doi : 10.1093/ibd/izac209
Inflammatory Bowel Diseases, Volume 28, Issue 12, December 2022, Page e153
